Company Watch

Ranbaxy acquires Ochoa Laboratories

Our News Bureau - Mumbai

Ranbaxy Laboratories has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories (Ochoa), a medium sized pharmaceutical formulations and dosage forms manufacturer located on the outskirts of New Delhi for its entire range of dermatological and lifestyle products.

The current market size of the dermatology segment in India is approximately Rs 1950 crore, growing rapidly at about 11 percent. Ranbaxy already has a strong presence in the dermatology market including steroids with products such as Zole-F, Suncros, Efflora, Fucidin and Teczine among others and with this buy consolidates its presence in this high-growth therapeutic segment.

The acquired brands command considerable equity with doctors and are market leaders in their respective categories. They complement Ranbaxy's existing derma portfolio. The products enjoy high margins because of their novelty and brand appeal and will be initially marketed in India.

Commenting on the acquisition, Malvinder Mohan Singh, the then Chairman, CEO & MD, Ranbaxy, said, “The move strengthens Ranbaxy’s domestic presence and market share in dermatology, a segment, for the company. I believe, the Indian pharma space is ripe for consolidation and Ranbaxy’s intent is to accelerate this trend with a view to reach commanding positions, especially in the high value chronic and acute therapy areas”.

Sanjeev Dani, Senior Vice President and Regional Director, Asia and CIS, Ranbaxy said, "Given Ranbaxy's extensive distribution capability, we are best positioned to leverage the vast potential of these brands while consolidating our product portfolio in dermatology."